Concepedia

Author

Martin C. Müller

Heidelberg UniversityORCID

Also Known As

M C Muller, M C Müller, M Müller, M. C. Muller, M. C. Müller, M. Müller, M.C. Müller, MARTIN MÜLLER, Martin C Muller, Martin C Müller

292

Publications

13.8K

Citations

58

H-Index

85

Concepts

All Affiliations

Heidelberg UniversityUniversity Hospital HeidelbergJena University HospitalMedizinische Fakultät MannheimSouth Australia Pathology
MC

About

Martin C. Müller is an author at Heidelberg University specializing in medicine, hematology, and cell biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

25

2.7K

2

Health Sciences

10

10

1.4K

3

Natural Sciences

4

4

200

4

Engineering

3

3

207

5

Social Sciences

2

2

359

Martin C. Müller

×

103

Publications

11.4K

Citations

54

H-Index

YearCitations

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz,

New England Journal of Medicine

2013

1.1K

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

Andreas Hochhaus, Hagop M. Kantarjian, Michele Baccarani,

Blood

2006

607

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber,

The Lancet Oncology

2018

587

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz,

Blood

2018

572

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Timothy P. Hughes, Andreas Hochhaus, Susan Branford,

Blood

2010

481

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

François Guilhot, Jane F. Apperley, Dong‐Wook Kim,

Blood

2007

371

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

Andreas Hochhaus, Michele Baccarani, Michael W. Deininger,

Leukemia

2008

352

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

Rüdiger Hehlmann, Michael Lauseker, Susanne Jung-Munkwitz,

Journal of Clinical Oncology

2011

321

Impact of Baseline <i>BCR-ABL</i> Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Timothy P. Hughes, Giuseppe Saglio, Susan Branford,

Journal of Clinical Oncology

2009

307

Reelin Deficiency and Displacement of Mature Neurons, But Not Neurogenesis, Underlie the Formation of Granule Cell Dispersion in the Epileptic Hippocampus

Christophe Heinrich, Naoki Nitta, Armin Flubacher,

Journal of Neuroscience

2006

300

Page 1